Stephen Dressel

VP, Strategic Finance & Analysis at Actinium Pharmaceuticals

Steve has nearly 20 years of corporate finance and commercial experience. He joins from Dewpoint Therapeutics, where he was Senior Director, Financial Planning & Analysis responsible for overseeing budgeting, long-term planning, and analyses. Previously, he was Senior Director, Head of Corporate Planning & Operations at Akebia Therapeutics, a publicly traded, commercial-stage company that developed and marketed Auryxia®. Steve spent 10 years at Regeneron in finance roles with increasing responsibility rising to Director, Commercial Finance supporting Praulent and EYLEA, a top 5 biologic launch, where he developed and managed 10-year forecasts and $250 million budgets. He transitioned to commercial roles in the cardiometabolic franchise culminating as Director, Market Access Strategy. He began his career at Bio-IB, a life science-focused investment bank, where he helped execute financings, M&A, licensing, and corporate advisory assignments. Steve has his MBA from Fordham University and a BA degree from the University of Colorado.

Location

Ridgefield, United States

Links

Previous companies

Dewpoint Therapeutics logo
Regeneron logo
Akebia Therapeutics logo

Org chart



Offices

This person is not in any offices